|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
This article explains the key changes that pharmaceutical companies and CMOs engaged in manufacturing and fill-finish need to consider, as well as what AbbVie Contract Manufacturing (AbbVie CMO) is doing to ensure its global operations and aseptic fill-finish sites are in compliance with the revised regulations….
|
|
 |
|
One way of streamlining tech transfer is to partner with a CMO demonstrating a proven track record across the entire drug development and manufacturing continuum. Not only will an experienced CMO partner have the scientific….
|
|
 |
|
This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.
|
|
 |
|
Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.
|
|
|
|
|
|
|
|
|
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Duke explain how systemic delivery approaches that leverage continuous dosing can address adherence issues and improve drug effectiveness while minimizing adverse reactions, and how a localized delivery approach can minimize total drug exposure, reduce off-target toxicities, and overcome targeting issues.
|
|
|
Anshul Gupte, PhD, says fortunately, enhanced solubility can be achieved using a variety of approaches. For oral solid dosage forms, well-established approaches include micronization, nanoparticles, amorphous solid dispersions (ASDs), lipid-based formulations, salts, and co-crystals.
|
|
|
Lucas Paulo Cusin, Kamlesh Oza, PhD, and Steven Smith, et al focus on the development of a customized functional coated capsule for the delivery of live biotherapeutics and demonstrate its effectiveness in the oral delivery of a sensitive proprietary microbiome ecosystem while simplifying the drug development process.
|
|
|
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
|
|
|
|
|
|
|
|
|

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2024. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.
|
|
|
|
|
|
 |
|
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
|
|
|
|
|
|
|
|
 |
|
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …
|
|
 |
|
By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.
Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …
|
|
 |
|
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.
Download our latest white paper, jointly authored with MeltPrep, to …
|
|
 |
|
What techniques should manufacturers employ when working with low-dose drug products?
By: Thomas Daggs, MBA, Vice President, Product Development & Quality Control, and Angelo Consalvo, Director of Manufacturing, Enteris BioPharma
Anyone who takes an oral tablet medication – whether prescribed …
|
|
|
|
|
Upcoming eNewsletter Features:
July 10 – Analytical Testing
August 7 – Injection Devices
|
|
|
|
|
|
|
|